Shares of Gilead Sciences, Inc. (NASDAQ:GILD) are trading higher into Friday’s trading session after Bank of America Securities upgraded the stock, highlighting an underappreciated growth potential in its core HIV business and emerging hematology/oncology franchises.
Here’s what investors need to know.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased